This study is extremely interesting because it examined the contentious relationship between statins and inhibition of ovarian cancer at the genetic level, and the results strongly suggest that statins that pharmacologically inhibit HMG-CoA reductase have the same effect. Here, HMGCR is linked to ovarian carcinoma.